Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 876 to 900 of 1150 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
1022 increased cell death (GO:0008219) oligodendrocyte (CL:0000128) 2265: Oligodendrocyte death, increased
1062 disrupted meiosis I (GO:0007127) oocyte (CL:0000023) 1882: Disrupted, initiation of meiosis of oogonia in the ovary
596 functional change organ (UBERON:0000062) 1135: Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
601 abnormal post-translational protein modification (GO:0043687) osteocalcin (PR:000030444) 1169: Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin
1061 decreased ovarian follicle development (GO:0001541) ovarian follicle (UBERON:0001305) 1883: Decreased, size of the ovarian reserve
1063 disrupted ovulation cycle (GO:0042698) ovarian follicle (UBERON:0001305) 405: disrupted, ovarian cycle
1087 decreased Premature ovarian failure (HP:0008209) ovarian follicle (UBERON:0001305) 2305: Premature ovarian Insufficiency
1065 decreased ovulation (GO:0030728) Ovum (FMA:67343) 1695: Impaired ovulation
167 increased signaling (GO:0023052) oxysterols receptor LXR-alpha (PR:000011395)
166 increased signaling (GO:0023052) oxysterols receptor LXR-beta (PR:000011394) 167: Activation, LXR
404 increased papilloma (MESH:D010212) 779: Increase, Papillomas/carcinomas (squamous cells)
11 occurrence Parkinsonian disorders (MESH:D020734) 896: Parkinsonian motor deficits
605 decreased signaling (GO:0023052) pendrin (PR:000015039) 1155: Inhibition, Pendrin
1079 abnormal embryonic organ development (GO:0048568) penis (UBERON:0000989) 2082: Hypospadias, increased
925 functional change pericyte cell (CL:0000669) 2096: Occurrence, (Micro)vascular dysfunction
22 increased receptor antagonist activity (GO:0048019) peroxisome proliferator-activated receptor alpha (PR:000013056) 998: Binding of antagonist, PPAR alpha
25 decreased receptor transactivation (GO:0035624) peroxisome proliferator-activated receptor alpha (PR:000013056) 858: Decreased, PPARalpha transactivation of gene expression
89 increased peroxisome proliferator activated receptor signaling pathway (GO:0035357) peroxisome proliferator-activated receptor alpha (PR:000013056) 227: Activation, PPARĪ±
181 decreased peroxisome proliferator activated receptor signaling pathway (GO:0035357) peroxisome proliferator-activated receptor alpha (PR:000013056)
182 decreased peroxisome proliferator activated receptor signaling pathway (GO:0035357) peroxisome proliferator-activated receptor delta (PR:000013057) 232: Decreased, PPAR-beta activation
168 increased peroxisome proliferator activated receptor signaling pathway (GO:0035357) peroxisome proliferator-activated receptor gamma (PR:000013058) 228: peroxisome proliferator activated receptor promoter demethylation
183 decreased peroxisome proliferator activated receptor signaling pathway (GO:0035357) peroxisome proliferator-activated receptor gamma (PR:000013058)
1038 increased cell activation involved in immune response (GO:0002263) Peyer's patch B cell (CL:0002402) None
351 decreased mating pheromone secretion (GO:0071834) pheromone (CHEBI:26013) 678: Reduced, Pheromone release
239 decreased gene expression (GO:0010467) phosphoenolpyruvate carboxykinase, cytosolic [GTP] (PR:000012416) 216: Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)